Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids

Journal of Neuroimmunology

Volumn 236, Issue 1-2, 2011, Pages 111-117

  Sanvito, Lara ^a,b   Tomita, Atsuko ^b   Chihara, Norio ^b   Okamoto, Tomoko ^c   Lin, Youwei ^c   Ogawa, Masafumi ^c   Gran, Bruno ^a   Aranami, Toshimasa ^b   Yamamura, Takashi ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Corticosteroids; Interferon ; Multiple sclerosis; Natural killer cells; Prednisolone

Indexed keywords

BETA1A INTERFERON; DEXAMETHASONE; INTERFERON BETA SERINE; KI 67 ANTIGEN; PREDNISOLONE;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE; CELL ISOLATION; CELL SUBPOPULATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CELLS, CULTURED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON-BETA; KI-67 ANTIGEN; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MULTIPLE SCLEROSIS; PREDNISOLONE;

EID: 79960197977     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.05.005     Document Type: Article

References (38)

1. Benczur M., Petrányl G.G., Pálffy G., Varga M., Tálas M., Kotsy B., Földes I., Hollán S.R. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin. Exp. Immunol. 1980, 39(3):657-662.
2. Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T.A., McFarland H., Henkart P.A., Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl Acad. Sci. USA 2006, 103:5941-5946.
3. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
4. Ciccone A., Beretta S., Brusaferri F., Galea I., Protti A., Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev, CD006264 2008.
5. Cohen J.A., Imrey P.B., Calabresi P.A., Edwards K.R., Eickenhorst T., Felton W.L., Fisher E., Fox R.J., Goodman A.D., Hara-Cleaver C., Hutton G.J., Mandell B.F., Scott T.F., Zhang H., Apperson-Hansen C., Beck G.J., Houghtaling P.L., Karafa M.T., Stadtler M. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009, 72:535-541.
6. De Jager P.L., Rossin E., Pyne S., Tamayo P., Ottoboni L., Viglietta V., Weiner M., Soler D., Izmailova E., Faron-Yowe L., O'Brien C., Freeman S., Granados S., Parker A., Roubenoff R., Mesirov J.P., Khoury S.J., Hafler D.A., Weiner H.L. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain 2008, 131:1701-1711.
7. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl 1):S17-S24.
8. Feng X., Yau D., Holbrook C., Reder A.T. Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J. Interferon Cytokine Res. 2002, 22(3):311-319.
9. Furlan R., Bergami A., Lang R., Brambilla E., Franciotta D., Martinelli V., Comi G., Panina P., Martino G. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J. Neuroimmunol. 2000, 111:86-92.
10. Gasperini C., Pozzilli C., Bastaniello S., Koudriavtseva T., Galgani S., Millefiori E., Paolillo A., Horsfield M.A., Bozzao L., Fieschi C. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology 1998, 50(2):403-406.
11. Garcia-Merino A., Barcenilla H., Diaz D., Monserrat J., Prieto A., Alvarez-Mon M. IFNbeta therapy progressively normalizes the increased ex vivo T lymphocyte apoptosis observed in active patients with multiple sclerosis. Clin. Immunol. 2009, 132:195-202.
12. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984, 133:1710-1715.
13. Gniadek P., Aktas O., Wandinger K.P., Bellmann-Strohl J., Wengert O., Weber A., von Wussow P., Obert H.J., Zipp F. Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients. J. Neuroimmunol. 2003, 137(1-2):187-196.
14. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58:169-178.
15. Graninger W.B., Steiner C.W., Graninger M.T., Aringer M., Smolen J.S. Cytokine regulation of apoptosis and Bcl-2 expression in lymphocytes of patients with systemic lupus erythematosus. Cell Death Differ. 2000, 7:966-972.
16. Hao J., Liu R., Piao W., Zhou Q., Vollmer T.L., Campagnolo D.I., Xiang R., La Cava A., Van Kaer L., Shi F.D. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 2010, 207:1907-1921.
17. Hartrich L., Weinstock-Guttman B., Hall D., Badgett D., Baier M., Patrick K., Feichter J., Hong J., Ramanathan M. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients. J. Neuroimmunol. 2003, 139:84-92.
18. Havrdova E., Zivadinov R., Krasensky J., Dwyer M.G., Novakova I., Dolezal O., Ticha V., Dusek L., Houzvickova E., Cox J.L., Bergsland N., Hussein S., Svobodnik A., Seidl Z., Vaneckova M., Horakova D. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult. Scler. 2009, 15:965-976.
19. Hunter C.A., Gabriel K.E., Radzanowski T., Neyer L.E., Remington J.S. Type I interferons enhance production of IFN-gamma by NK cells. Immunol. Lett. 1997, 59:1-5.
20. Kastrukoff L.F., Lau A., Wee R., Zecchini D., White R., Paty D.W. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J. Neuroimmunol. 2003, 145:103-114.
21. Kastrukoff L.F., Morgan N.G., Zecchini D., White R., Petkau A.J., Satoh J., Paty D.W. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. Neurology 1999, 52:351-359.
22. Khan O.A., Dhib-Jalbut S.S. Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients. Neurology 1998, 51(3):738-742.
23. Leussink V.I., Jung S., Merschdorf U., Toyka K.V., Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 2001, 58:91-97.
24. Lopez F., Belloc F., Lacombe F., Dumain P., Reiffers J., Bernard P., Boisseau M.R. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 1991, 12:42-49.
25. Lunemann J.D., Munz C. Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis?. Brain 2008, 131:1681-1683.
26. Martin J.F., Perry J.S., Jakhete N.R., Wang X., Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J. Immunol. 2010, 185:1311-1320.
27. Misu T., Fujihara K., Nakashima I., Miyazawa I., Okita N., Takase S., Itoyama Y. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002, 125:2460-2468.
28. Myhr K.M., Mellgren S.I. Corticosteroids in the treatment of multiple sclerosis. Acta Neurol. Scand. Suppl. 189, 2009, 73-80.
29. Perini P., Wadhwa M., Buttarello M., Meager A., Facchinetti A., Thorpe R., Biasi G., Gallo P. Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients. J. Neuroimmunol. 2000, 105:91-95.
30. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58:840-846.
31. Ravnborg M., Sorensen P.S., Andersson M., Celius E.G., Jongen P.J., Elovaara I., Bartholome E., Constantinescu C.S., Beer K., Garde E., Sperling B. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010, 9(7):672-680.
32. Saraste M., Irjala H., Airas L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol. Sci. 2007, 28:121-126.
33. Sorensen P.S., Mellgren S.I., Svenningsson A., Elovaara I., Frederiksen J.L., Beiske A.G., Myhr K.M., Sogaard L.V., Olsen I.C., Sandberg-Wollheim M. NORdic trial of oral methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009, 8:519-529.
34. Takahashi K., Miyake S., Kondo T., Terao K., Hatakenaka M., Hashimoto S., Yamamura T. Natural killer type 2 bias in remission of multiple sclerosis. J. Clin. Investig. 2001, 107:R23-R29.
35. Vandenbark A.A., Huan J., Agotsch M., La Tocha D., Goelz S., Offner H., Lanker S., Bourdette D. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J. Neuroimmunol. 2009, 215:125-128.
36. Winkler-Pickett R., Young H.A., Cherry J.M., Diehl J., Wine J., Back T., Bere W.E., Mason A.T., Ortaldo J.R. In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J. Immunol. 2008, 180:4495-4506.
37. Wyllie A.H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980, 284:555.
38. Zhang B., Yamamura T., Kondo T., Fujiwara M., Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186:1677-1687.